Cullinan Therapeutics Inc
CGEM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.09B
Close$
$1.45
91.5% downside
Current Fair Value
91.5% downsideOvervalued by 91.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.09 Billion |
|---|---|
| Enterprise Value | $1.01 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.72 |
| Beta | -0.01 |
| Outstanding Shares | 59,201,000 |
Return
| Return on Equity | -60.36% |
|---|---|
| Return on Assets | -54.85% |
| Return on Invested Capital | -66.72% |
Valuation & Multiples
| P/E Ratio | -4.72 |
|---|---|
| PEG | -197.24 |
| Price to Sales | - |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.13 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.83
Average shareholder expectationRevenue Estimate
$3.67 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.80
Average shareholder expectationRevenue Estimate
$3.67 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 28.94% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.39%▼ 110.35% |
|---|---|
| Total Invested | $4.06M▼ 99.56% |
| Investors Holding | 13▼ 164.00% |
ESG Score
No data
About Cullinan Oncology Inc
24 employeesCullinan Management is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s strategy is to build a pi...